NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

u/BIO9999
Walgreens will likely deliver $NWBO DCVax-L
Ray Tancredi, a noted figure due to his prolific background in the specialty pharmacy sector and numerous leadership roles at Walgreens, notably as the Divisional Vice President of Specialty Pharmacy Development and Brand Rx/Vaccine Purchasing, delivers insightful and valuable contributions annually at Asembia’s Specialty Pharmacy Summit. His expertise guides discussions surrounding the integration of innovative cell and gene therapies into the specialty pharmacy realm, addressing the multifaceted challenges, strategic considerations, and potential remediations aimed at enhancing patient care and bolstering therapeutic outcomes.

In his most recent keynote address during the conference's inaugural business session, Tancredi shed light on a curated roster of cell and gene therapies he anticipates will secure approval in 2023. His comprehensive analysis can be explored through the following overview, which intriguingly positions DCVax-L at the epicenter of the cell therapy section: [https://www.ajmc.com/view/an-overview-of-the-specialty-therapy-pipeline-in-2023].

Significantly, Walgreens is meticulously shaping its strategic blueprint to emerge as the preferred provider of cell and gene therapies for a broad public audience. Evidence of this ambition can be gleaned from their official webpage: [https://www.alliancerxwp.com/business/pharma].

Highlighting the ubiquity and accessibility of Walgreens, it's noteworthy that approximately 80% of the American population resides within a five-mile radius of a Walgreens outlet. With an expansive operational presence spanning North America, Latin America, and Europe, and a recent foray into the Chinese market through a strategic acquisition, Walgreens' global footprint is impressive.

At the conclusion of the previous year, Walgreens had 393 VillageMD primary care clinics in its locations, thanks to its majority stake in VillageMD, which recently additionally undertook an $8.9B acquisition of Summit Health. This robust network of clinics significantly bolsters Walgreens' capacity to deliver DCVax-L injections in a convenient manner to patients, paralleling the administration of conventional vaccines. This aligns with the Cancer Moonshot program's ambitious goal of localizing cancer care to the greatest possible extent.

As the landscape of healthcare continues to evolve, keen eyes will undoubtedly monitor the unfolding dynamic between this Dow Industrials component and $NWBO, especially as DCVax-L begins its journey to the market.